A--OLIGONUCLEOTIDE SYNTHESIS SEQUENCE SERVICES FOR ON GOING RESEARCH PROJECT

The US Army Medical Research Acquisition Activity (USAMRAA) intends to negotiate, on a sole source basis, under authority of 10 U.S.C. 2304 (1), with Oligos Etc. for purchase of oligonucleotide synthesis sequence services. Synthesis services were performed by Oligos Etc in FY 2009 and before for custom primers needed to support forward and quote mark in house quote mark diagnostic assays which use a common chemistry for quality assurance. These are operation critical items for sample testing and support of forward units. It is paramount that this research project's results be scientifically sound and therefore capable of withstanding the greatest amount of scientific question and scrutiny. The only way to insure the consistency and scientific merit of the tests is for them to be performed by the same source. Minute differences in test results of this kind occur between sources. Those small differences between vendors are enough to compromise the science. Therefore, the same source must provide all custom primers at the 10 uM scale, HPLC purified, tested and certified throughout the research project. Oligos Etc is uniquely qualified to synthesize custom primers at the 10 uM scale, HPLC purify them, test them for quality control by capillary electrophoresis, and provide the results of that testing along with a detailed Certificate of Analysis. USAMRIID's research project may be seriously compromised if synthesis services are not obtained from Oligos Etc. No solicitation package will be issued. However, responses received by 28 December 2012, will be considered by the Government. A determination by the Government not to compete the proposed acquisition based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a future competitive procurement.